Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Gross Margin (2016 - 2025)

United Therapeutics (UTHR) has disclosed Gross Margin for 17 consecutive years, with 86.91% as the latest value for Q4 2025.

  • Quarterly Gross Margin changed N/A to 86.91% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 87.92% through Dec 2025, changed N/A year-over-year, with the annual reading at 87.92% for FY2025, 131.0% down from the prior year.
  • Gross Margin hit 86.91% in Q4 2025 for United Therapeutics, down from 87.38% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 94.39% in Q1 2022 to a low of 7000.0% in Q4 2023.
  • Historically, Gross Margin has averaged 282.83% across 5 years, with a median of 89.24% in 2024.
  • Biggest five-year swings in Gross Margin: surged 197bps in 2022 and later plummeted -708804bps in 2023.
  • Year by year, Gross Margin stood at 91.67% in 2021, then decreased by -4bps to 88.04% in 2022, then tumbled by -8051bps to 7000.0% in 2023, then surged by 101bps to 88.9% in 2024, then dropped by -2bps to 86.91% in 2025.
  • Business Quant data shows Gross Margin for UTHR at 86.91% in Q4 2025, 87.38% in Q3 2025, and 89.03% in Q2 2025.